Tg Therapeutics (TGTX) Current Leases (2019 - 2026)

Tg Therapeutics' Current Leases history runs 8 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• In Q1 2026, Current Leases rose 63.26% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $1.8 million (up 63.26% YoY), while the FY2025 annual figure was $1.0 million, down 9.77% from the prior year.
• Current Leases for Q1 2026 stood at $1.8 million, up from $1.0 million in the prior quarter.
• The five-year high for Current Leases was $1.8 million in Q1 2026, with the low at $1.0 million in Q4 2025.
• The 5-year median for Current Leases is $1.4 million (2023), against an average of $1.4 million.
• The sharpest annual moves came in 2024 and 2026: Current Leases declined 19.99% in 2024, then jumped 63.26% in 2026.
• Tg Therapeutics' Current Leases stood at $1.6 million in 2022, then dropped by 8.54% to $1.4 million in 2023, then fell by 19.99% to $1.2 million in 2024, then slipped by 9.77% to $1.0 million in 2025, then surged by 74.52% to $1.8 million in 2026.
• Business Quant data shows TGTX's Current Leases at $1.8 million in Q1 2026, $1.0 million in Q4 2025, and $1.1 million in Q3 2025.